Novo Nordisk to slash prices of weightloss drugs in US / Photo: SCOTT OLSON - GETTY IMAGES NORTH AMERICA/AFP/File
CMSC
-0.2100
The Prague Post - Novo Nordisk to slash prices of weightloss drugs in US
EUR
-
AED 4.195799
AFN 72.545262
ALL 94.373378
AMD 420.516584
ANG 2.04552
AOA 1047.664661
ARS 1669.737728
AUD 1.638439
AWG 2.056485
AZN 1.915954
BAM 1.951192
BBD 2.306888
BDT 140.408382
BGN 1.931817
BHD 0.431912
BIF 3415.632271
BMD 1.142492
BND 1.481278
BOB 7.897348
BRL 5.893655
BSD 1.145341
BTN 108.143585
BWP 15.544485
BYN 3.204703
BYR 22392.836377
BZD 2.303589
CAD 1.618819
CDF 2587.74347
CHF 0.924013
CLF 0.026309
CLP 1035.451024
CNY 7.740154
CNH 7.746636
COP 3930.319806
CRC 519.587055
CUC 1.142492
CUP 30.276029
CVE 110.678859
CZK 24.200773
DJF 203.963878
DKK 7.474495
DOP 66.955446
DZD 152.554686
EGP 56.834273
ERN 17.137375
ETB 181.827173
FJD 2.562437
FKP 0.863375
GBP 0.862895
GEL 3.021908
GGP 0.863375
GHS 12.830461
GIP 0.863375
GMD 83.401519
GNF 10035.686741
GTQ 8.715416
GYD 239.095302
HKD 8.956735
HNL 30.470429
HRK 7.532562
HTG 149.621405
HUF 352.498091
IDR 20415.183327
ILS 3.394743
IMP 0.863375
INR 108.117981
IQD 1496.664064
IRR 1570926.021079
ISK 143.94249
JEP 0.863375
JMD 180.980659
JOD 0.809973
JPY 184.591272
KES 147.836101
KGS 99.910684
KHR 4584.258768
KMF 492.413889
KPW 1028.242887
KRW 1757.180697
KWD 0.352642
KYD 0.954488
KZT 558.256206
LAK 25191.940644
LBP 102310.127428
LKR 382.985073
LRD 208.165004
LSL 18.819309
LTL 3.37348
LVL 0.691082
LYD 7.343339
MAD 10.682125
MDL 20.141622
MGA 4832.739286
MKD 61.615135
MMK 2399.138755
MNT 4089.242301
MOP 9.248709
MRU 45.779688
MUR 54.622615
MVR 17.663374
MWK 1986.06828
MXN 19.859978
MYR 4.729575
MZN 73.000192
NAD 18.819227
NGN 1563.054356
NIO 41.849596
NOK 11.099621
NPR 173.396514
NZD 2.004319
OMR 0.439295
PAB 1.142901
PEN 4.207825
PGK 4.985548
PHP 70.18666
PKR 317.784078
PLN 4.27669
PYG 6982.421087
QAR 4.165551
RON 5.236383
RSD 117.347575
RUB 84.836309
RWF 1673.179024
SAR 4.288561
SBD 9.214242
SCR 15.148116
SDG 686.068212
SEK 11.007165
SGD 1.478321
SHP 0.852985
SLE 28.276973
SLL 23957.48288
SOS 654.557716
SRD 42.764032
STD 23647.270512
STN 24.67782
SVC 10.021778
SYP 126.281999
SZL 18.747925
THB 37.723361
TJS 10.600763
TMT 4.010146
TND 3.326363
TOP 2.750846
TRY 53.098673
TTD 7.767244
TWD 36.134608
TZS 3002.733115
UAH 51.513002
UGX 4172.146184
USD 1.142492
UYU 45.70206
UZS 13704.187802
VES 704.763427
VND 30072.66526
VUV 135.216519
WST 3.143904
XAF 655.814443
XAG 0.01805
XAU 0.000276
XCD 3.087641
XCG 2.064242
XDR 0.815619
XOF 655.808704
XPF 119.331742
YER 272.655331
ZAR 18.772074
ZMK 10283.794611
ZMW 20.301498
ZWL 367.881846
- Antetokounmpo joining Miami Heat in blockbuster: reports
- Fineanganofo rethinks Newcastle move after All Blacks call-up
- 'Let's be realistic': Haaland cools Norway's World Cup expectations
- Stocks fluctuate after Wall St sell-off, crude holds losses on peace talks
- Lightning, downpour, a two-hour delay: bad weather hits the World Cup
- Ultra-reclusive Turkmenistan slowly opens up to tourists
- Two-goal Haaland fires Norway into World Cup last 32
- Marc Bloch, historian and Resistance hero, joins France's Pantheon greats
- Last one the best one? How Messi keeps doing it at World Cup
- Ronaldo 'a role model' says Portugal coach after slow World Cup start
Novo Nordisk to slash prices of weightloss drugs in US
Danish drugmaker Novo Nordisk, which is struggling with competition for its anti-obesity treatments, said Tuesday that it will sharply cut prices for its flagship drugs in the US, announcing a 50 percent cut for Wegovy and 35 percent for Ozempic.
"This decision applies to all doses of these medicines and reflects Novo Nordisk's commitment to enhancing affordability for patients and both public and private payers dealing with the complexities of the evolving US healthcare system," the company said in a statement.
Effective January 1, 2027, the list price will be $675 for a month's worth of Wegovy, which currently costs around $1,350 a month.
Ozempic and Rybelsus, treatments that each currently come to about $1,000, will also be priced $675.
Novo Nordisk said the price reduction is meant to make it possible to reach more patients.
"Lowering the list price of Wegovy and Ozempic is the best approach to address the unprecedented opportunity to help more than 100 million people living with obesity and over 35 million people with type 2 diabetes in the United States," Jamey Millar, executive vice president of Novo Nordisk's US Operations, said.
In early February, Novo Nordisk vowed legal against US chain Hims & Hers for offering a copycat of the new pill version of Wegovy.
Limited production capacity for the blockbuster drug led the FDA to temporarily allow pharmacies to create so-called "compound" or copycat versions of Wegovy and Ozempic, an analogue used to treat diabetes.
That authorisation expired last May 22 but Novo Nordisk has complained of copycat versions of its drugs still being available.
Ozempic is an injectable anti-diabetic treatment that became popular on social media for its slimming properties.
Wegovy, which has the same active ingredient as Ozempic in a different dose, is a weight-loss drug and is also available in pill form.
Both treatments use analogues of the hormone GLP-1, which regulates blood glucose levels and appetite.
Shares in Novo Nordisk have taken a beating in recent weeks after it warned in early February of lower sales revenue in the United States as intensified competition pushes down prices.
They fell 3.8 percent in afternoon trading in Copenhagen.
J.Simacek--TPP
